Adenosine Injection, 6mg/2ml (3mg/ml) Vial
NDC Package 51662-1201-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Adenosine Injection, 6mg/2ml (3mg/ml) Vial is adenosine injection is indicated for the following.Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). Marketed by Hf Acquisition Co. Llc, Dba Health First, this product is identified by NDC 51662-1201 and is authorized under FDA application ANDA078076.

Identification & Billing

NDC Package Code
51662-1201-1
Package Description
2 mL in 1 VIAL
Product Code
51662-1201
11-Digit Billing Format
51662120101
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Adenosine Injection, 6mg/2ml (3mg/ml) Vial
Dosage Form
-
Usage Information
Adenosine injection is indicated for the following.Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration.It is important to be sure the adenosine solution actually reaches the systemic circulation ( See Dosage and Administration) Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co. Llc, Dba Health First
FDA Application #
ANDA078076
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-14-2018
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1201-1 identifies a specific commercial package of 2 ml in 1 vial of Adenosine Injection, 6mg/2ml (3mg/ml) Vial, labeled by Hf Acquisition Co. Llc, Dba Health First. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Hf Acquisition Co. Llc, Dba Health First on July 14, 2018. The current certification is valid through December 31, 2025.

How is this Hf Acquisition Co. Llc, Dba Health First product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662120101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1201-1
11-Digit CMS (5-4-2)
51662-1201-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.